GlassScriptPhysician profile
Nicholas John Schmidt
NPI 1235592221
$18,108.45
in general payments reported to CMS, 2019-2025
60 companies · $3,351 in 2025
The $3,351 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,314 · 2024: $13K · 2025: $3,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $8,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,000.00 |
| Food and Beverage | $8,108.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene, LTD. | $10,000.00 | 2024 | |
| Merck Sharp & Dohme LLC | $783.42 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $504.57 | 2023-2025 | |
| Pfizer INC. | $480.33 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $447.25 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Astrazeneca Pharmaceuticals LP | $401.38 | 2023-2025 | Calquence, Enhertu, Tagrisso |
| Celgene Corporation | $360.09 | 2023-2025 | Reblozyl, Pomalyst, Abecma |
| Regeneron Healthcare Solutions, INC. | $302.11 | 2023-2025 | Libtayo |
| Gilead Sciences, INC. | $300.20 | 2024-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $277.00 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Takeda Pharmaceuticals U.S.A., INC. | $257.81 | 2023-2025 | Iclusig, Ninlaro, Fruzaqla |
| Sobi, INC | $257.13 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $248.72 | 2023-2025 | |
| Genentech USA, INC. | $245.51 | 2023-2025 | Venclexta, Polivy, Lunsumio |
| Lilly USA, LLC | $218.71 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $210.60 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Janssen Biotech, INC. | $201.57 | 2023-2025 | Rybrevant, Darzalex, Erleada |
| Incyte Corporation | $192.16 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Acrotech Biopharma INC. | $183.36 | 2023-2025 | Beleodaq |
| Daiichi Sankyo INC. | $180.99 | 2023-2025 | Injectafer, Enhertu, Datroway |
| Abbvie INC. | $150.18 | 2024-2025 | |
| Beone Medicines USA, INC. | $148.97 | 2025 | Brukinsa |
| Genzyme Corporation | $137.60 | 2023-2025 | |
| Beigene USA, INC. | $111.92 | 2024-2025 | Brukinsa |
| Puma Biotechnology, INC. | $97.25 | 2024-2025 | |
| Seagen INC. | $94.17 | 2023 | Adcetris, Padcev, Tukysa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.78 | 2023-2025 | Gilotrif |
| Adaptive Biotechnologies Corporation | $77.64 | 2023-2024 | Clonoseq |
| Ipsen Biopharmaceuticals, INC | $73.14 | 2024-2025 | Onivyde, Somatuline Depot |
| Stemline Therapeutics INC. | $68.47 | 2024 | Orserdu, Elzonris |
| Kyowa Kirin, INC. | $66.60 | 2025 | |
| Immunocore Limited | $62.04 | 2024-2025 | Kimmtrak |
| Alexion Pharmaceuticals, INC. | $59.05 | 2024-2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $55.81 | 2023-2025 | Qinlock, Tgct |
| Array Biopharma INC | $54.60 | 2023-2025 | Lorbrena, Mektovi, Braftovi |
| Taiho Oncology, INC. | $52.44 | 2024 | |
| Legend Biotech USA INC. | $51.08 | 2025 | Carvykti |
| Kite Pharma, INC. | $46.04 | 2025 | Yescarta |
| Servier Pharmaceuticals LLC | $43.37 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $42.58 | 2025 | Danziten |
| Karyopharm Therapeutics INC. | $39.37 | 2024 | Xpovio |
| Adc Therapeutics America, INC. | $37.25 | 2025 | |
| Springworks Therapeutics, INC. | $35.78 | 2025 | Gomekli, Ogsiveo |
| Sumitomo Pharma America, INC. | $27.65 | 2024-2025 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $26.51 | 2024 | Monoferric |
| Blueprint Medicines Corporation | $26.24 | 2024 | Ayvakit |
| Novocure INC. | $24.82 | 2024 | |
| Geron Corporation | $24.56 | 2025 | Rytelo |
| Alnylam Pharmaceuticals INC. | $23.34 | 2024 | Givlaari |
| Eisai INC. | $23.27 | 2023 | |
| Forte Bio-Pharma LLC | $23.20 | 2023 | Prolate, Nalocet |
| Genmab U.S., INC. | $22.06 | 2025 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $21.41 | 2025 | |
| Shield Therapeutics INC | $20.84 | 2025 | |
| Syndax Pharmaceuticals, INC. | $19.31 | 2025 | |
| Spectrum Pharmaceuticals INC. | $18.02 | 2025 | Rolvedon |
| Caris Mpi, INC. | $17.78 | 2025 | Mi Cancer Seek |
| G1 Therapeutics, INC. | $16.27 | 2023 | Cosela |
| Tersera Therapeutics LLC | $15.45 | 2025 | Xermelo |
| Myriad Genetic Laboratories, INC. | $14.68 | 2024 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.